Hologic

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery. The Diagnostics segment consists of products used to aid in the screening and diagnosis of human diseases. The GYN Surgical segment involves the NovaSure Endometrial Ablation System, the MyoSure Hysteroscopic Tissue Removal System, and the Fluent Fluid Management System. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Hologic exceeds Q1 earnings, eyes growth in women's health

Hologic's Q1 performance surpassed expectations, driven by strong organic growth and strategic initiatives. The company's commitment to women's health, financial strength, and focus on innovation position it well for future growth. Challenges in Breast Health highlight areas for improvement, while opportunities in new markets and products offer avenues for expansion.

Hologic surpasses Q2 expectations, eyes international growth and women's health

Hologic's Q2 performance exceeded expectations, driven by robust organic revenue growth and strong margins across divisions.
While facing challenges like COVID-related revenue declines and seasonal factors, the company's strategic strengths in women's health and international expansion present growth opportunities.
To sustain growth, Hologic must navigate macro uncertainties, balance growth drivers, and capitalize on opportunities in diagnostics and global expansion.
Overall, Hologic's solid financial results, increased revenue guidance, and strategic initiatives position the company for continued success in the healthcare market.

Hologic excels in Q3 earnings, eyes global growth amid challenges

Hologic delivered strong financial results in Q3 2023, driven by robust revenue growth and strategic product offerings across its divisions.
While facing margin challenges and geopolitical uncertainties, the company remains optimistic about sustaining growth and enhancing profitability through operational improvements.
With a focus on innovation, global expansion, and cautious M&A strategies, Hologic is well-positioned to capitalize on opportunities and navigate challenges in the healthcare market.

Hologic surpasses revenue targets, eyes international growth and strategic M&A

Hologic delivered strong financial performance in Q4 2023, exceeding revenue and EPS targets while emphasizing women's health and innovation.
The company's focus on international growth, strategic capital allocation, and product portfolio strength position it well for continued success.
Challenges in regulatory compliance, M&A decisions, and market dynamics require careful navigation for sustained growth.
Opportunities in international expansion, strategic M&A, and product innovation offer avenues for future growth and market leadership.

Hologic surpasses Q1 revenue expectations, eyes international growth opportunities

Hologic delivered strong Q1 2024 results, exceeding revenue guidance and showcasing robust financial performance with organic growth of 5.2% ex-COVID.
The company's focus on innovation, market expansion, and strong customer relationships positions it well for continued growth and success beyond COVID testing.
While facing challenges such as tough comps in Q2 and potential tax rate impacts, Hologic's disciplined growth strategies and commitment to transformative initiatives offer opportunities for future expansion.
With a strong emphasis on AI capabilities, market expansion, and strategic M&A, Hologic is poised for sustained growth and market leadership in the healthcare sector.

Hologic beats Q2 revenue targets, eyes international growth opportunities

Hologic exceeded revenue and EPS expectations in Q2 2024, showcasing growth in key business segments.
While facing challenges in certain revenue streams, the company is focused on international expansion and margin improvement.
Opportunities lie in leveraging international growth, strategic acquisitions, and product utilization trends.
Overall, Hologic's performance reflects resilience post-COVID and strategic focus on innovation and market positioning.

Hologic surpasses Q3 revenue expectations, eyes international growth opportunities

Hologic's Q3 performance reflects resilience and growth across key business segments, supported by strategic investments and operational excellence. With a focus on innovation and international expansion, the company is well-positioned for sustained growth and value creation in the evolving healthcare landscape.

Hologic exceeds Q4 earnings, eyes international growth and new products

Hologic's Q4 2024 earnings call showcased strong performance, strategic strengths, and growth opportunities. Challenges include maintaining margin expansion and balancing international growth. The company's focus on durable revenue base and new product pipeline sets a positive outlook for fiscal 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products, that focuses on women’s health and well-being through early detection and treatment. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment is involved in a portfolio of solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology and treatment. The Diagnostics segment offers a range of products, which are used primarily to aid in the screening and diagnosis of human diseases. The GYN Surgical segment is involved in hysteroscopic endometrial ablation systems, tissue removal systems, fluid management systems, and laparoscopic tissue ablation systems and tools. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

Abbott Labs

Exact Sciences

QIAGEN

Thermo Fisher Scientific

Given the current testing requirements across the world, the diagnostic testing business for COVID-19 is rapidly evolving.

Coronavirus Drives Testing Stocks: Is There Room for More Upside?

Becton, Dickinson and Co.

Fluidigm

Eli Lilly

Luminex

PerkinElmer

QuidelOrtho Corp

You know what they say! To the most sensitive tests go the spoils.

The FDA Just Ranked Coronavirus Tests by Sensitivity. Here's What That Means

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #BCAM--Hologic Announces Partnership with the Black Women’s Health Imperative and RAD-AID to Tackle Breast Cancer Screening

Hologic Announces Multi-Year, Multi-Pronged Commitment to Tackling Breast Cancer Screening Disparities for Black Women in Partnership with the Black Women’s Health Imperative and RAD-AID

Investors continue to be optimistic about Hologic (HOLX) on robust growth of the Diagnostics segment and regulatory approvals.

Here's Why You Should Hold on to Hologic (HOLX) Stock for Now

The FDA approves Hologic's (HOLX) Panther Fusion SARS-CoV-2 assay and pooling protocol to curb the unrelenting spread of coronavirus.

Hologic (HOLX) Receives EUA for Asymptomatic Coronavirus Testing

Shares of Hologic Inc. were up 3.6% in premarket trading on Monday after the company said it had received emergency use authorization from the Food and Drug Administration for a diagnostic test specifically aimed at people with asymptomatic COVID-19 infections. Hologic said it is the first company to offer a test screening asymptomatic individuals.

Hologic shares gain on authorization of COVID-19 test for asymptomatic people

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #covid19--Hologic Granted FDA Emergency Use Authorization for Asymptomatic COVID-19 Testing with Panther Fusion SARS-CoV-2 Assay

Hologic Granted FDA Emergency Use Authorization for Asymptomatic COVID-19 Testing with Panther Fusion SARS-CoV-2 Assay

Activision Blizzard

Brinker International

Lennar

SunPower

Invest in top-ranked stocks that are likely to beat earnings estimates in the upcoming release.

Tap 5 Top Stocks With Strong Earnings Beat Prospects

Fresenius Medical Care

Let's grab these three stocks that have continued to show tremendous promise despite market volatility resulting from the coronavirus pandemic.

3 MedTech Outperformers to Grab Amid September Pullback

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic Announces Pricing of Offering of $950 Million of 3.250% Senior Notes Due 2029

Hologic Announces Pricing of Offering of $950 Million of 3.250% Senior Notes Due 2029

Hologic Inc. HOLX, +3.53% said Monday it is planning to offer $950 million of nine-year bonds, joining the many companies issuing record levels of debt during the pandemic.

Hologic plans $950 million offering of 9-year bonds

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic Announces Offering of $950 Million of Senior Notes Due 2029

Hologic Announces Offering of $950 Million of Senior Notes Due 2029

Hologic (HOLX) is in the news Friday after announcing updated guidance for its fiscal Q4 of 2020 that sent HOLX stock soaring higher.
The post Hologic News: HOLX Stock Heads 4% Higher on Bright Outlook appeared first on InvestorPlace.

Hologic News: HOLX Stock Heads 4% Higher on Bright Outlook

Shares of Hologic Inc. HOLX, +1.16% shot up 10% in premarket trading Friday, after the diagnostics products and medical imaging systems company raised its fiscal fourth-quarter revenue outlook, to put it well above analyst expectations, citing increased production and strong sales of COVID-19 tests.

Hologic's stock soars after revenue outlook raised well above analyst expectations

Quest Diagnostics

These three stocks have consolidated their strong competitive positions in recent months.

3 Lucrative Coronavirus Testing Stocks to Buy Right Now

Hologic (HOLX) introduces features to update Brevera Breast Biopsy System in order to transform patient experience and enhance workflow.

Hologic Updates Breast Biopsy System to Enhance Workflow

Ameren

Greif

Hain Celestial Group

PriceSmart

The markets were trading flat as consumer spending data for July beat expectations, coming in at 6.2% in June and 8.6% in May, after falling 12.9% in April. Per usual, tech is keeping Nasdaq afloat this morning.

Best Stocks To Buy Today Amid Positive Consumer Spending Data

Hologic (HOLX) reported earnings 30 days ago. What's next for the stock?

Why Is Hologic (HOLX) Down 11.7% Since Last Earnings Report?

Rival Abbott is looking to become the dominant player in the coronavirus test arena.

Here's Why Quidel, Hologic, and Quest Diagnostics Shares Fell Today

ABIOMED

Bio-Rad Laboratories

Danaher

DexCom

IDEXX Laboratories

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

West Pharmaceutical Services

Savvy investors should consider adding these stocks to their portfolio to enhance its performance and diversity.

These 10 Stocks Are the Biggest S&P 500 Healthcare Winners of 2020

Hologic's (HOLX) newly-acquired product line is set to complement its market-leading MyoSure products for hysteroscopic removal of fibroids.

Hologic's Acessa Health Buyout to Broaden GYN Surgical Line

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #Acessa--Hologic to Acquire Acessa Health, Innovator in Minimally Invasive Solutions for Treatment of Fibroids

Hologic to Acquire Acessa Health, Innovator in Minimally Invasive Solutions for Treatment of Fibroids

Yamana Gold

Forestar Group

M.D.C. Holdings

Spectrum Brands Hlds

The long-term growth rate is a useful tool for value investors.

Long-Term Growth Rates Rising On These 5 Buy-Ranked Stocks

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #COVID19--Hologic Launches Validated Pooling Protocol for COVID-19 Testing

Hologic Launches Validated Pooling Protocol for COVID-19 Testing

Hologic (HOLX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

News for Hologic Stock (HOLX)